Pflug Koory’s CRISPR Therapeutics CRSP Stock Holding History

Pflug Koory’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.58K	Hold	84	–	–	﹤0.01%	375
2026 Q1	$4K	Hold	84	–	–	﹤0.01%	374
2025 Q4	$4.41K	Hold	84	–	–	﹤0.01%	369
2025 Q3	$5.44K	Hold	84	–	–	﹤0.01%	353
2025 Q2	$4.09K	Hold	84	–	–	﹤0.01%	364
2025 Q1	$2.86K	Hold	84	–	–	﹤0.01%	361
2024 Q4	$3.31K	Hold	84	–	–	﹤0.01%	361
2024 Q3	$3.95K	Buy	+84	New	+$4.26K	﹤0.01%	357
2024 Q1	$5.72K	Hold	84	–	–	﹤0.01%	347
2023 Q4	$5.26K	Hold	84	–	–	﹤0.01%	357
2023 Q3	$3.81K	Hold	84	–	–	﹤0.01%	366
2023 Q2	$4.72K	Hold	84	–	–	﹤0.01%	364
2023 Q1	$3.8K	Hold	84	–	–	﹤0.01%	383
2022 Q4	$3K	Hold	84	–	–	﹤0.01%	388
2022 Q3	$5K	Hold	84	–	–	﹤0.01%	396
2022 Q2	$5K	Hold	84	–	–	﹤0.01%	377
2022 Q1	$5K	Hold	84	–	–	﹤0.01%	391
2021 Q4	$6K	Hold	84	–	–	﹤0.01%	380
2021 Q3	$9K	Hold	84	–	–	﹤0.01%	358
2021 Q2	$14K	Hold	84	–	–	0.01%	343
2021 Q1	$10K	Hold	84	–	–	0.01%	358
2020 Q4	$13K	Hold	84	–	–	0.01%	327
2020 Q3	$7K	Hold	84	–	–	﹤0.01%	331
2020 Q2	$6K	Hold	84	–	–	﹤0.01%	341
2020 Q1	$4K	Hold	84	–	–	﹤0.01%	354
2019 Q4	$5K	Buy	+84	New	+$4.59K	﹤0.01%	367

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pflug Koory's CRSP Position: Q2 2026 in Review

Pflug Koory held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 84 shares worth $4.58K. The position accounts for ﹤0.01% of the portfolio, ranked #375.

Pflug Koory first reported a position in CRSP in Q4 2019 and has held it in 26 quarters since. The position peaked at $14K in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Pflug Koory held 84 shares of CRISPR Therapeutics worth $4.58K as of Q2 2026.
Pflug Koory left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Pflug Koory's portfolio in Q2 2026, its #375 holding.
Pflug Koory first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 26 quarters since.
Pflug Koory's CRISPR Therapeutics position peaked at $14K in Q2 2021.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Pflug Koory's 13F filing for Q2 2026, filed 21 Jul 2026.